

~~(3) IDENTIFY THE CIRCUMSTANCES UNDER WHICH PRESCRIPTION MONITORING DATA ARE PROVIDED TO AN AUTHORIZED RECIPIENT, WITH SUCH CIRCUMSTANCES TO PARALLEL AS CLOSELY AS IS APPROPRIATE AN AUTHORIZED RECIPIENT'S AUTHORITY TO ACCESS SIMILAR CONFIDENTIAL INFORMATION UNDER FEDERAL AND STATE LAWS AND REGULATIONS IN EFFECT AT THE TIME THE PROGRAM WAS ESTABLISHED;~~

~~(4) IDENTIFY THE CIRCUMSTANCES UNDER WHICH AN AUTHORIZED RECIPIENT MAY DISCLOSE PRESCRIPTION MONITORING DATA PROVIDED BY THE PROGRAM;~~

~~(5) IDENTIFY THE CIRCUMSTANCES UNDER WHICH A FEDERAL LAW ENFORCEMENT AGENCY, A STATE OR LOCAL LAW ENFORCEMENT AGENCY, OR A LICENSING ENTITY THAT HAS RECEIVED PRESCRIPTION MONITORING DATA SHALL CONSULT WITH THE MULTIDISCIPLINARY CONSULTATION TEAM ESTABLISHED UNDER § 21-2A-04 OF THIS SUBTITLE ABOUT THE INTERPRETATION OF THE PRESCRIPTION MONITORING DATA;~~

~~(6) PROMOTE APPROPRIATE AND REAL TIME, IF FEASIBLE, ACCESS TO PRESCRIPTION MONITORING DATA BY DISPENSERS AND PRESCRIBERS TO HELP PREVENT SUBSTANCE ABUSE AND PRESCRIPTION DRUG DIVERSION;~~

~~(7) REQUIRE THE BOARD TO APPLY FOR FEDERAL GRANT MONEY, AS APPROPRIATE;~~

~~(8) ENSURE THAT THE PROGRAM IS DESIGNED TO:~~

~~(i) PREVENT, TO THE FULLEST EXTENT POSSIBLE, THE BURDEN ON DISPENSERS IN THEIR COMPLIANCE WITH THE REQUIREMENTS OF THIS SUBTITLE; AND~~

~~(ii) RECEIVE PRESCRIPTION MONITORING DATA IN A MANNER COMPATIBLE WITH EXISTING DATA SUBMISSION PRACTICES OF DISPENSERS; AND~~

~~(9) ENSURE THAT:~~

~~(i) CONFIDENTIAL OR PRIVILEGED PATIENT INFORMATION IS KEPT CONFIDENTIAL; AND~~

~~(ii) RECORDS OR INFORMATION PROTECTED BY THE PRIVILEGE BETWEEN A HEALTH CARE PROVIDER AND A PATIENT, OR OTHERWISE REQUIRED BY LAW TO BE HELD CONFIDENTIAL, IS FILED IN A MANNER THAT, EXCEPT AS OTHERWISE PROVIDED IN § 21-2A-06 OF THIS SUBTITLE, DOES NOT DISCLOSE THE IDENTITY OF THE PERSON PROTECTED.~~